Blog
RSS FeedPosted by Michael Wonder on 23 Jan 2019
Vertex’s CF drug gets label extension as pricing row continues Vertex’s CF drug gets label extension as pricing row continues
23 January 2019 - While UK cystic fibrosis patients continue their long wait for access to Vertex’s Orkambi, the drug ...
Posted by Michael Wonder on 23 Jan 2019
Future costs in cost-effectiveness analyses: past, present, future
23 January 2019 - There has been considerable debate on the extent to which future costs should be included in cost-effectiveness ...
Posted by Michael Wonder on 22 Jan 2019
Sanofi UK marketing authorisation granted for Sanofi Pasteur’s trivalent influenza vaccine (split virion, inactivated) high dose (TIV high dose)
21 January 2019 - UK is the only European country where TIV high dose is approved. ...
Posted by Michael Wonder on 21 Jan 2019
NHS England sees off AbbVie's hepatitis C legal challenge
21 January 2019 - Claims of unfair process dismissed by High Court. ...
Posted by Michael Wonder on 21 Jan 2019
New agreement on branded drugs for the NHS
18 January 2019 - The new Voluntary Scheme for Branded Medicines Pricing and Access began on 1 January and was ...
Posted by Michael Wonder on 18 Jan 2019
NICE OK for Bravtovi skin cancer drug
18 January 2019 - NICE has recommended Pierre Fabre’s Bravtovi (encorafenib) and Mektovi (binimetinib) combination as an option for some ...
Posted by Michael Wonder on 18 Jan 2019
Patient groups fail to declare financial interests during NICE assessments
16 January 2019 - Patients’ groups involved in assessing treatments for the NHS often fail to disclose their financial interests, ...
Posted by Michael Wonder on 18 Jan 2019
Thousands of adults with chronic lymphocytic leukaemia to benefit from new treatment option
18 January 2019 - Thousands of people will benefit as NICE recommends venetoclax with rituximab for adults with relapsed or refractory ...
Posted by Michael Wonder on 17 Jan 2019
NICE approval for Verzenios in metastatic breast cancer
17 January 2019 - NICE has recommended Eli Lilly’s Verzenios (abemaciclib) in combination with an aromatase inhibitor as treatment option ...
Posted by Michael Wonder on 16 Jan 2019
EFPIA response to the UK parliament’s decision to reject the Brexit withdrawal agreement and political declaration
15 January 2019 - EFPIA notes the UK parliament’s decision to reject the Brexit withdrawal agreement and political declaration. ...
Posted by Michael Wonder on 16 Jan 2019
One in six Britons considers stockpiling food and medicine for Brexit
16 January 2019 - 4% of consumers already storing emergency provisions: Kantar. ...
Posted by Michael Wonder on 16 Jan 2019
The UK’s new five year pricing agreement
16 January 2019 - Pharma has agreed to capped growth again – in exchange for uptake promises. ...
Posted by Michael Wonder on 12 Jan 2019
Time running out for ‘no-deal’ Brexit medicines laws
11 January 2019 - Needs parliament clearance before 29 March. ...
Posted by Michael Wonder on 10 Jan 2019
NICE publishes final guidance on another use of Keytruda for patients with NSCLC
10 January 2019 - This time it is for patients with untreated, metastatic non-squamous non-small cell lung cancer. ...
Posted by Michael Wonder on 10 Jan 2019
New migraine drug not cost-effective NICE says in draft guidance
10 January 2019 - NICE has said that a new drug for preventing migraine is not a cost effective use of ...